Displaying 1 - 12 of 59
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Displaying 1 - 12 of 59